Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study

Affiliations

• ¹ Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
• ² Janssen Research and Development, Titusville, NJ, USA.
• ³ Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.
• ⁴ Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.
• ⁵ Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
• ⁶ College of Medicine and Health, University of Exeter, Exeter, UK.
• ⁷ Faculty of Medicine, Islamic University of Gaza, Gaza City, Palestine.
• ⁸ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
• ⁹ College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.
• ¹⁰ Critical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
• ¹¹ University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
• ¹² Real-World Evidence, Trial Form Support, Barcelona, Spain.
• ¹³ Faculty of Pharmacy, Cairo University, Cairo, Egypt.
• ¹⁴ National Institute for Health and Care Excellence, London, UK.
• ¹⁵ Regeneron Pharmaceuticals, Tarrytown, NY, US.
• ¹⁶ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
• ¹⁷ School of Population Health, UNSW Sydney, Sydney, Australia.
• ¹⁸ College of Medicine, University of Arizona, Tucson, AZ, USA.
• ¹⁹ DHC Technologies, Beijing, China.
• ²⁰ Division of Population Health and Genomics, University of Dundee, Dundee, UK.
• ²¹ Department of Public Health, University of Southern Denmark, Odense, Denmark.
• ²² School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
• ²³ Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
• ²⁴ Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
• ²⁵ Universitat Autònoma de Barcelona, Barcelona, Spain.
• ²⁶ College of Engineering, University of Arizona Tucson, AZ, USA.
• ²⁷ Bayer Pharmaceuticals, Sant Joan Despí, Spain.
• ²⁸ School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
• ²⁹ School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
• ³⁰ Nanfang University, Southern Medical University, Guangzhou, China.
• ³¹ Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.
• ³² VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System, Salt Lake City, Utah, USA; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
• ³³ VA Informatics and Computing Infrastructure, Tennessee Valley Healthcare System, VA Medical Center, Nashville, TN, USA.
• ³⁴ Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.
• ³⁵ Department of Preventive Medicine and Public Health, Yonsei University College of Medicine, Seoul, South Korea.
• ³⁶ Department of Biomedical Informatics, Columbia University, New York, NY, USA.
• ³⁷ IQVIA, Cambridge, MA, USA.
• ³⁸ Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, USA.
• ³⁹ OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, USA.
• ⁴⁰ Janssen Research and Development, Titusville, NJ, USA [email protected].
• ⁴¹ Columbia University Irving Medical Center, New York, NY, USA.